Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents (vol 71, 116962, 2022)

被引：0
|
作者：
Li, Ling [1 ,2 ]
Zhao, Huiting [2 ]
Peng, Xiaopeng [3 ]
Liu, Jin [2 ]
Mai, Ruiyao [2 ]
Chen, Jingxuan
Lin, Lin [4 ]
Chen, Ting [4 ]
Yan, Jun [5 ,6 ]
Shi, Jiaolong [5 ,6 ]
Chen, Jianjun [2 ,5 ,6 ]
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 8, Shenzhen 518033, Peoples R China
[2] Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou 510515, Peoples R China
[3] Gannan Med Univ, Coll Pharm, Ganzhou 314000, Peoples R China
[4] Southern Med Univ, Nanfang Hosp, Dept Stomatol, Guangzhou 510515, Peoples R China
[5] Southern Med Univ, Dept Gen Surg, Guangzhou 510515, Guangdong, Peoples R China
[6] Southern Med Univ, Nanfang Hosp, Sch Clin Med 1, Guangdong Prov Key Lab Precis Med Gastrointestinal, Guangzhou 510515, Guangdong, Peoples R China
来源：
BIOORGANIC & MEDICINAL CHEMISTRY | 2024年 / 111卷
关键词：
D O I：
10.1016/j.bmc.2024.117840
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：1
相关论文
共 43 条
  • [21] Discovery of Thieno[2,3-d]pyrimidine-based KRAS G 12D inhibitors as potential anticancer agents via combinatorial virtual screening
    Li, Ling
    Liu, Jin
    Yang, Zichao
    Zhao, Huiting
    Deng, Bulian
    Ren, Yichang
    Mai, Ruiyao
    Huang, Junli
    Chen, Jianjun
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 233
  • [22] Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors
    Marcell Baranyi
    Eszter Molnár
    Luca Hegedűs
    Zsófia Gábriel
    Flóra Gréta Petényi
    Fanni Bordás
    Violetta Léner
    Ivan Ranđelović
    Mihály Cserepes
    József Tóvári
    Balázs Hegedűs
    József Tímár
    British Journal of Cancer, 2024, 130 : 1059 - 1072
  • [23] Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors
    Baranyi, Marcell
    Molnar, Eszter
    Hegedus, Luca
    Gabriel, Zsofia
    Petenyi, Flora Greta
    Bordas, Fanni
    Lener, Violetta
    Randelovic, Ivan
    Cserepes, Mihaly
    Tovari, Jozsef
    Hegedus, Balazs
    Timar, Jozsef
    BRITISH JOURNAL OF CANCER, 2024, 130 (06) : 1059 - 1072
  • [24] Discovery of novel coumarin-based KRAS-G12C inhibitors from virtual screening and Rational structural optimization
    Shi, Jian-Tao
    Hou, Su-Juan
    Cheng, Lei
    Zhang, Hao-Jie
    Mu, Hong-Xia
    Wang, Qing-Shan
    Wang, Zhao-yang
    Chen, Shi-Wu
    BIOORGANIC CHEMISTRY, 2024, 148
  • [25] Structure- based drug discovery of a selective, covalent KRas G12C inhibitor with oral activity in animal models of cancer
    Fischer, John
    Baer, Brian
    Ballard, Joshua
    Blake, James
    Bouhana, Karyn
    Brandhuber, Barbara
    Briere, David
    Burgess, Laurence
    Burkard, Michael
    Chiang, Harrah
    Chicarelli, Mark
    Christensen, James
    Davidson, Kevin
    Gaudino, John
    Hallin, Jill
    Hanson, Lauren
    Hee, Kenneth
    Hicken, Erik
    Hinklin, Ronald
    Marx, Matthew
    Mejia, Macedonio
    Olson, Peter
    Savechenkov, Pavel
    Sudhakar, Niranjan
    Tang, Tony
    Vigers, Guy
    Zecca, Henry
    Fell, Jay
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
  • [26] Discovery of novel phosphatidylcholine-specific phospholipase C drug-like inhibitors as potential anticancer agents
    Eurtivong, Chatchakorn
    Pilkington, Lisa I.
    van Rensburg, Michelle
    White, Reuben M.
    Brar, Harpreet Kaur
    Rees, Shaun
    Paulin, Emily K.
    Xu, Chris Sun
    Sharma, Nabangshu
    Leung, Ivanhoe K. H.
    Leung, Euphemia
    Barker, David
    Reynisson, Johannes
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 187
  • [27] Combining Fundamental Kinetics and Standard Alkylation Assays to Prioritize Lead-like KRAS G12C Inhibitors (vol 9, pg 51508, 2024)
    Frommlet, Alexandra
    Nguyen, Lan K.
    Saabye, Matt
    Endres, Nicholas F.
    Mulvihill, Melinda M.
    Quinn, John G.
    ACS OMEGA, 2025, 10 (11): : 11642 - 11642
  • [28] Design, synthesis, and evaluation of purine and pyrimidine-based KRAS G12D inhibitors: Towards potential anticancer therapy
    Park, So-Youn
    Saralamma, Venu Venkatarame Gowda
    Nale, Sagar Dattatraya
    Kim, Chang Joong
    Jo, Yun Seong
    Baig, Mohammad Hassan
    Cho, Junghwan
    HELIYON, 2024, 10 (07)
  • [29] A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system
    Wu, Lisha
    Xu, Maosheng
    Li, Xueqin
    Aierken, Dilinuer
    Yu, Jinxiu
    Qin, Tao
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [30] Structure-based drug discovery of MRTX1257: A selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer
    Marx, Matthew
    Baer, Brian
    Ballard, Joshua
    Blake, James
    Bouhana, Karyn
    Briere, David
    Burgess, Laurence
    Burkhard, Michael
    Chiang, Harrah
    Chicarelli, Mark
    Christensen, James
    Fischer, John
    Hallin, Jill
    Mejia, Macedonio
    Olson, Peter
    Savechenkov, Pavel
    Sudhakar, Niranjan
    Tang, Tony
    Vigers, Guy
    Fell, Jay
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
12345